Comparative Pharmacology
Head-to-head clinical analysis: METRO I V versus METRO I V IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V versus METRO I V IN PLASTIC CONTAINER.
METRO I.V. vs METRO I.V. IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
None Documented
None Documented
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)